| Identification | Back Directory | [Name]
ZK824859 | [CAS]
2271122-53-1 | [Synonyms]
(R)-2-((6-((3'-(Aminomethyl)-5-methyl-[1,1'-biphenyl]-3-yl)oxy)-3,5-difluoropyridin-2-yl)oxy)butanoic acid | [Molecular Formula]
C23H22F2N2O4 | [MDL Number]
MFCD32011808 | [MOL File]
2271122-53-1.mol | [Molecular Weight]
428.43 |
| Chemical Properties | Back Directory | [Boiling point ]
542.7±50.0 °C(Predicted) | [density ]
1.291±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [pka]
2.62±0.10(Predicted) |
| Hazard Information | Back Directory | [Uses]
ZK824859 is an oral available and selective urokinase plasminogen activator (uPA) inhibitor with IC50s of 79?nM, 1580?nM and 1330?nM for human uPA, tPA, and plasmin, respectively[1]. | [in vivo]
ZK824859 (50, 25 and 10?mg/kg; b.i.d.; 25 days) is used in a chronic mouse EAE model. ZK 824859 completely prevents the development of disease. However, two lower doses (25 and 10?mg/kg) have no effect on clinical scores[1]. | Animal Model: | Female SJL mice with chronic mouse EAE model[1] | | Dosage: | 50, 25 and 10?mg/kg | | Administration: | B.i.d.; 25 days | | Result: | Prevented the development of disease at 50?mg/kg completely. However, 25 and 10?mg/kg had no effect on clinical scores. |
| [References]
[1] Islam I, et al. Discovery of selective urokinase plasminogen activator (uPA) inhibitors as a potential treatment for multiple sclerosis. Bioorg Med Chem Lett. 2018 Nov 1;28(20):3372-3375. DOI:10.1016/j.bmcl.2018.09.001 |
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
| Company Name: |
A.J Chemicals
|
| Tel: |
91-9810153283 |
| Website: |
www.ajchemicals.com |
|